Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of oral solithromycin vs azithromycin for community-acquired pneumonia
jRCT2080224917Phase 3Completed
- Sponsor
- FUJIFILM Toyama Chemical
- Start
- Oct 2019
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of solithromycin in community-acquired pneumonia (CAP) and Pneumococcal pneumonia (PP) (2 arms), sponsored by FUJIFILM Toyama Chemical. Started Oct 2019; status: completed.
02
Drugs
solithromycin
03
Conditions
community-acquired pneumonia (CAP)Pneumococcal pneumonia (PP)
Beyond the preview
Go deeper on jRCT2080224917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224917.